Table 3.

Severe immune-related adverse events associated with anti-CTLA-4 and anti-PD-1/-PDL-1 therapy.

Event	%
Rash (general)a	13.4–26.0
Rash (maculo-papular)	1.5–17.5
Pruritis	14.1–35.4
Vitiligo	74.3–11.0
Pneumonitis	0.4–7.8
Colitis	0.5–7.0
Diarrhea	4.1–9.0
Hypothyroidism	1.2–7.0
Hyperthyroidism	0.3–7.1
Adrenal insufficiency	0.2–5.5

^aReviewed in Ref. (59).